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Abstract
Background: In the field of experimental stem cell therapy, intra-arterial (IA) delivery yields the best results
concerning, for example, migrated cell number at the targeted site. However, IA application also appears to be
associated with increased mortality rates and infarction. Since many rodent studies systemically apply 1 × 106 cells,
this could also be a consequence of engrafted cell number. The aim of this study was therefore to investigate the
effect of different doses of adipose tissue-derived stem cells (ASCs) on engraftment rates and stroke outcome
measured in vivo using 9.4-T high-field magnetic resonance imaging (MRI).
Methods: Male Wistar rats (n = 43) underwent a middle cerebral artery occlusion (MCAo) for 45 or 90 min, followed
by IA delivery of either saline or 1 × 106, 3 × 105, or 5 × 104 ASCs pre-labelled with very small superparamagnetic
iron oxide particles (VSOPs). MRI (9.4-T) analysis was performed 48 h and 9 days post-MCAo. Lesion volumes were
assessed by analysis of T2-weighted images and cell signal tracking showing cell engraftment and active cell
migration by an improved T2*-analysis.
Results: The ASC-derived signal intensity increased in the affected hemisphere 48 h post MCAo with injected cell
number (p < 0.05). The analysis of stroke volumes revealed an increased infarction after injection of 1 × 106 ASCs
compared to controls or application of 5 × 104 ASCs (p < 0.05). At 9 days post-MCAo, injection of 3 × 105 ASCs
resulted in reduced infarct volumes (p < 0.05). Correspondingly, MRI analysis revealed no changes in cell numbers
between both MRI examinations but showed active ASC migration to the site of infarction.
Conclusion: Our results confirm that IA injection is an efficient way of targeting damaged brain tissue but its
usefulness strongly depends on the right dose of delivered stem cells since this factor has a strong influence on
migration rate and infarct volume, with better results for doses below 1 × 106 cells. Future challenges will include
the determination of therapeutic doses for best cellular engraftment and stroke outcome.
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Background
Stem cell (SC) therapy has gained tremendous attention
as the expectation in regenerative medicine seems to be
obvious: to replace diseased or dying tissue areas with
new healthy cells. Adipose tissue-derived stem cells
(ASCs) can be extensively extracted from subcutaneous
human adult adipose tissue and are increasingly being
recognised for their proliferating capacity in cell culture
as well as for their multipotency [1–4]. Additionally,
their immune-privileged and immunomodulatory prop-
erties potentially allow for allogeneic transplantation into
immunocompetent recipients and support tissue repair
through immunosuppressive effects [5–10]. Further-
more, ASCs secrete numerous trophic factors which
modulate inflammation, remodelling, and apoptosis, e.g.,
during stroke. This suggests they can be used as an alter-
native to largely unsuccessful drug approaches [9, 11].
However, a lot of important questions in this promising
field of non-drug therapy have still not been answered
sufficiently; for example, what is the best delivery route
or the right dose of cells for application. Regarding the
route of application, results indicate that, in contrast to
locally transplanted SCs, systemically (that is, intraven-
ously (IV) or intra-arterially (IA)) injected cells have
potent anti-inflammatory effects, promote brain remod-
elling, and induce functional neurological recovery [12].
However, there are also differences within systemic ap-
plication routes that can dramatically affect cell engraft-
ment. IV injection is a minimally invasive and therefore
clinically highly relevant technique, but one very import-
ant point in the field of SC therapy is the question of
how to bring enough active components, that is SCs, to
the target tissue. With regards to engraftment rates, IV
injection leads to delayed and poor engraftment due to
long-distance migration, and filtering organs (predomin-
antly the lungs) trapping a large amount of cells [13, 14].
More promising results concerning the migration, distri-
bution, and cell number at the target site have been ob-
tained after IA injection. However, it seems that this
benefit comes at the cost of higher mortality rates and
even increased infarction [14–16]. It is questionable if
this observation is necessarily linked to IA administra-
tion or to the amount of SCs injected since, despite the
fact that experimental details have gained more attention
in recent studies, individual settings still differ signifi-
cantly and have not been tested sufficiently, especially
the correct amount, that is the therapeutic dose of cells.
Most of the recent studies engrafting SCs in rodents sys-
temically used 1 × 106 cells [14, 16–18]. It will therefore
be important to question how much influence this
parameter has on SC therapy, especially on mortality
rate, traceability of engrafted cells, and infarct size. Until
now, no study has ever investigated the relationship be-
tween different doses of IA delivered stem cells, cell
engraftment, and migration behaviour, as well as the ef-
fect on stroke outcome, although this is of tremendous
importance with regard to stem cell treatment in
humans. In this study, we have investigated the effect of
different amounts of ASCs, pre-labelled with very small
superparamagnetic iron oxide particles (VSOP), on cell
migration and distribution as well as the effect on infarct
size in vivo in rat brain parenchyma using 9.4-T small
animal magnetic resonance imaging (MRI) at two given
times. Cells were injected IA into the external carotid
artery after middle cerebral artery occlusion (MCAo).
Methods
Cell culture and ASC labelling
Cells were processed and characterized as described pre-
viously and cultured in 5% CO2 at 37 °C in mesenchymal
stem cell (MSC) growth medium supplemented with
10% MSC growth supplement, 2% L-glutamine, and 0.1%
gentamicin sulphate/amphotericin-B (MSCGM Single
Quots, Lonza, Walkersville, MD, USA) [19]. Myco-
plasma contaminations were excluded by regular tests
during cell culture. Subcultivation was performed at
densities of 2 × 105 cells per 75 cm2 cell culture flask to
prevent confluency. For experiments, the passage num-
ber was below ten. Before engraftment, ASCs were la-
belled with electrostatically stabilized VSOPs (VSOP 5
nm Flu vitro, Ferropharm, Teltow, Germany) as de-
scribed previously. VSOPs have been proven to be better
suited for in vivo cell labelling due to their monomer cit-
rate coating resulting in diameters of only 4–9 nm and
the easy and stable labelling of cells via endocytosis [20,
21]. To verify optimal growth behaviour, and to exclude
any cytotoxic effect caused by cell labelling, growth
curves were obtained by seeding 5 × 105 VSOP labelled
and unlabelled ASCs and assessing vital and dead cells
up to 14 days. The test was performed five times.
Additionally, possible VSOP-mediated cytotoxicity was
determined by measuring the release of lactate dehydro-
genase (LDH) using the Cytotoxicity Detection Kit
(Roche, Mannheim, Germany). Unlabelled ASCs served
as negative controls and ASCs treated with 2% Triton X
as positive controls. Values were calculated by subtract-
ing the background control (cell culture medium) and
mean values from three seeded wells for each point
(negative control = unlabelled cells; positive control = un-
labelled cells re-suspended with cytotoxic 2% Triton and
cells labelled with 3 mM VSOPs) were calculated. The
test was performed four times. Results are described in
Additional file 1: S-1 and shown in Additional file 2:
Figure S1A and B.
Animals
This manuscript was written in accordance with the AR-
RIVE (Animal research: reporting in vivo experiments)
Grudzenski et al. Stem Cell Research & Therapy  (2017) 8:96 Page 2 of 14
guidelines [22]. Male Wistar rats originated from
Charles River Laboratories (Sulzfeld, Germany) and were
kept in the Central Facility for Medical Research (ZMF)
of the University Medical Center, Mannheim, under a 12
h light cycle with food and drinking water available ad
libitum. Animals were immunocompetent and did not
receive immunosuppressive therapy.
MCAo via filament model and cell application via the
external carotid artery
Anaesthesia was introduced with isoflurane 2.5%
vaporised in O2 (med oxygen) in 43 male Wistar rats at
the age of 12 weeks and with a weight of 383 ± 76.2 g. An-
aesthesia was maintained at 1.5% during surgery (Abbott,
Wiesbaden, Germany) via a face mask. Body temperature
was maintained at 37 °C with an electric heating pad and
feedback control via a rectal temperature probe. Arterial
blood gases (pO2, pCO2, pH, oxygen saturation) and heart
rate were controlled using the radiometer ABL80 Flex
(Radiometer GmbH, Willich, Germany).
Right-sided MCAo via the external carotid artery
(ECA) was performed as described previsouly using
silicon rubber-coated monofilaments with a diameter
of 390 μm (Doccol Corporation, Sharon, MA, USA)
[23, 24]. Non-invasive cerebral blood flow (CBF) mea-
surements to ensure vessel occlusion were performed
by laser Doppler measurement of the affected right
hemisphere using the moor VMS-PC V2.0 system
(Moor Instruments, Millway, UK). Only animals with
visible vessel occlusion and a significant drop in CBF
were included in the study.
Due to the high mortality rates after MCAo of 90 min
and administration of 1 × 106 cells, we included animals
with a reduced occlusion time of 45 min for all groups.
The group of animals receiving 5 × 104 cells all under-
went MCAo for 45 min. After MCAo, 0.5 ml NaCl 0.9%
was injected containing no cells (control animals; MCAo
45 min, n = 8; MCAo 90 min, n = 9), 1 × 106 ASCs
(MCAo 45 min, n = 4; MCAo 90 min, n = 3), 3 × 105
ASCs (MCAo 45 min, n = 6; MCAo 90 min, n = 6), or
5 × 104 ASCs (n = 7; all MCAo 45 min). After rinsing
with 0.15 ml NaCl 0.9%, the ECA was ligated perman-
ently and ligation on the common carotid artery was
removed to allow reperfusion. The laser Doppler probe
was removed and both wounds were closed. Mortality
rates are described in Additional file 1: S-2.
MRI measurements
Infarct localization and cell signals were measured 48 h
and 9 days post MCAo in vivo using a 9.4-T Biospec 94/
20 USR small animal system equipped with 740 mT/m
gradients and a 1H surface cryogenic probe (Bruker,
Ettlingen, Germany). An ischaemic lesion was defined
based on hyperintense T2-weighted images.
Diffusion-weighted images (DWIs) and the corre-
sponding maps of apparent diffusion coefficient (ADC)
were obtained to identify signals obtained by T2- and
T2*-weighted images as an infarct and tissue develop-
ments such as necrosis and oedema. DWIs were
acquired using a respiratory-triggered single-shot spine-
cho echo-planar imaging (SS-EPI) sequence using the
following parameters: 30 gradient directions and seven
b-values (b = 0, 500, 1000, 1500, 2000, 2500, 3000 s/
mm2) along each direction, Δ/δ = 10/2.5 ms, TR/TE =
3000/21.5 ms, FOV = 14 × 11 mm, matrix size = 100 × 78,
20 slices with a slice thickness/spacing of 0.8/0.2 mm,
bandwidth = 300000 Hz, NEX = 1, and a total acquisition
time of 9 min. ADC maps were calculated using Bruker
software. T2-weighted images were acquired with a
coronal T2-weighted RARE sequence using the same
geometry as the SS-EPI: TR/TE = 3300/60 ms, echo train
length = 4, FOV = 14 × 11 mm, matrix size = 320 × 256,
bandwidth = 110000 Hz, NEX = 4, and a total acquisition
time of 4 min.
Labelling cells with VSOPs leads to a strong decrease
in the transverse relaxation time of water protons diffus-
ing close to the cells, resulting in turn in signal loss in
T2*-weighted gradient echo images [25]. Thus VSOP-
labelled cells can be visualized by decreased signals in
T2*-weighted gradient echo images. Visualization was
realised by an axial gradient-echo FLASH sequence
(TR = 50 ms, TE = 8.7 ms, FA = 15_, FOV = 26.88 ×
17.92 × 8.96 mm3, MA = 768 × 512 × 256, NA = 2, tacq =
2 h 23 min, Res = 35 × 35 × 35 μm3).
MRI analysis of infarct sizes and cell signal intensity
All analyses were performed blind to the treatment
protocol or functional outcome of the tested animals.
MRI analysis was performed 48 h post-stroke. The
difference in cell signal intensity (ΔCSI) was measured
48 h post MCAo in seven T2*-weighted MR images per
animal, exactly defined by anatomical structures. The
affected and contralateral hemisphere was defined as the
region of interest (ROI) and mean signal intensity as well
as standard deviation (SD) were measured within each
ROI using Image J software (National Institute of Health,
MD, USA). The mean ΔCSI between affected (affect.
hemi) and contralateral hemisphere (contralat. hemi)
was then calculated and averaged over seven slices using
the following formula:






For infarct analysis, twenty T2-weighted MR images per
individual were obtained and analysed. The hyperintense
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infarct area of every MRI slide was calculated using Image
J. The area was then multiplied by slice thickness to calcu-
late infarct volumes per MRI slide. The infarct area of the
interslice gaps was calculated as the mean infarct area of
two neighbour slices. The volumes of interslice gaps were
then also calculated by multiplying the intergap thickness
by the mean infarct area of two neighbour slices. Final
infarct volumes were obtained by adding all the volumes
up and were calculated as a percentage of the total indi-
vidual brain volume of each animal (which was calculated
in the same way).
Residual infarct sizes 9 days post-MCAo were calcu-
lated as the percentage of infarct sizes obtained after 48
h to determine individual changes in infarct size in each
animal. Due to signal changes within 9 days caused by
tissue transformation, ambiguous hypointense signals in
T2*-weighted images had to be re-analysed by deleting
unspecific signals and leaving ASC-derived hypointense
voxels. Therefore, all obtained T2*-weighted images per
animal (twenty MRI slices corresponding to the numbers
of T2-weighted images) were corrected for inhomogene-
ities using bias field correction [26]. Brains were seg-
mented using a customized version of the brain
extraction tool in FSL (Oxford Centre for Functional
Magnetic Resonance Imaging of the Brain (FMRIB)’s
Software Library). Images were normalized by setting
the individual image mean to 1000. All brains were
aligned using FSL-FLIRT (FMRIB’s Linear Image Regis-
tration Tool) as described previously [27]. In Matlab
(The MathWorks Inc., Natick, MA, USA) the de-noised
(median filter) image was subtracted from the original
image, and the absolute value of the result was taken.
Finally, a wiener filter (local noise reduction) was
applied. Voxels in the affected hemisphere having inten-
sities higher than the mean + 2SD of voxel intensity in
the right hemisphere were considered speckled voxels.
When overlaid on the original data, these voxels
contained both hyper- and hypointense voxels. Based on
a histogram analysis, only the hypointense voxels were
selected and considered as ASC-derived signals.
Histology
After incubation of harvested brains under deep isoflurane
anaesthesia by transcardial perfusion with 4% acid-free
formaldehyde overnight, 2-mm blocks were dehydrated in
ethanol and xylol (Roth, Karlsruhe, Germany) and
embedded in paraffin. For tissue staining procedures,
4-μm sections were dewaxed in xylene and rehydrated
in alcohol and distilled water. Prussian blue (PB)
staining was performed using the Accustain® Iron
Stain Kit according to the manufacturer’s guidelines
(Sigma-Aldrich, St. Louis, MO, USA). Nuclei were
counterstained using nuclear fast red 0.1% (Merck,
Darmstadt, Germany) for 10 min. For 3,3′-
diaminobenzidine (DAB) and fluorescent staining, antigen
retrieval was performed using either citrate buffer (DAKO
REAL target retrieval solution, pH 6.0; DAKO, Hamburg,
Germany) or tris (hydroxymethyl)aminomethane/ethyl-
enediaminetetraacetic acid (TRIS/EDTA) buffer, pH 9.0
(TRIS, Merck, Darmstadt, Germany; EDTA, SERVA elec-
trophoresis, Heidelberg, Germany) depending on the anti-
body used. For displaying VSOP fluorescence after
rehydration in alcohol, sections were incubated with
4′,6-diamidino-2-phenylindole (DAPI; 1:500; KPL,
Gaithersburg, USA) overnight at 4 °C, washed thor-
oughly with 1× phosphate-buffered saline (PBS), pH
7.4, and mounted in Mowiol (Roth, Karlsruhe,
Germany). Results are described and representative
images of ASC identification and localisation via
staining of PB and VSOP fluorescence are shown in
Additional file 1: S-3 and Additional file 3: Figure S2.
DAB staining was performed according to the manu-
facturer’s guidelines using the ImmPACT DAB Kit
(Vector Laboratories, Burlingame, CA, USA). Antibody
dilutions were 1:100 for anti-Ki67 (#MAB4190) and 1:30
for anti-human mitochondria (#MAB1273) (both mono-
clonal, mouse; Merck Millipore, Darmstadt, Germany).
Cells were counterstained with hematoxylin (Hollborn&-
Soehne, Leipzig, Germany). Results and representative
images of human cell identification as well as viability
testing via staining of human mitochondria and Ki67 are
shown in Additional file 1: S-3 and Additional file 4:
Figure S3A and B. After dehydrating steps in alcohol, PB
and DAB stained sections were preserved in Eukitt (O.
Kindler GmbH & CO, Freiburg, Germany).
Microscopic imaging, datasets, and statistics
A Leica DM 4500 B fluorescence microscope and Leica
IM50 Image Manager Software were used (Leica,
Wetzlar, Germany) for bright field and image acquisition.
The dataset supporting the conclusions of this article
are included within the article (see data ranges, medians,
and interquartile ranges (IQRs) in the Tables). For statis-
tical analysis, a standard software package (SPSS for
windows, “SPPS Inc.”, Chicago, IL, USA) was used and
the two-sided Mann-Whitney U test was chosen for
calculation of statistical comparisons. A p value ≤0.05
was considered significant.
Results
MRI analysis of ASC-derived signals 48 h post MCAo
Forty-eight hours after IA transplantation, ASCs were
distributed discretely throughout the entire lesion area
in the ipsilateral side of the brain as shown by hypoin-
tense dots in representative T2*-weighted images. The
intensity of the hypointense signal increased visibly with
the number of cells injected (Fig. 1a). To quantify this
effect, the mean ΔCSI was calculated for each animal to
Grudzenski et al. Stem Cell Research & Therapy  (2017) 8:96 Page 4 of 14
evaluate differences in CSI between the ischaemic and
non-ischaemic hemisphere (for data range, medians, and
IQRs for ΔCSI, see Table 1). Results showed that MCAo
duration did not affect ΔCSI for the control group and
the group receiving 3 × 105 cells. For animals receiving
1 × 106 cells, the occlusion times could not be compared
due to restricted data for the group undergoing MCAo
for 90 min; however, due to a comparable ΔCSI in the
first-mentioned groups, a statistical comparison was per-
formed for every group independently of occlusion time.
ΔCSI values were significantly lower for control animals
than for animals treated with 5 × 104 cells (p < 0.01), 3 ×
105 cells (p < 0.001), or 1 × 106 cells (p < 0.01) (Fig. 1b).
MRI analysis of infarct size 48 h post MCAo
To evaluate the effect of ASC engraftment on infarction,
T2-weighted MR images were obtained from the same
animals and MRI slices. Forty-eight hours after MCAo
and ASC injection, the lesion area in the ipsilateral side
of the brain was visible as a hyperintense signal and in-
creased visibly after engraftment of 1 × 106 cells (Fig. 2a).
Fig. 1 MRI analysis of ASC-derived signals 48 h post-MCAo. a Representative T2*-weighted images show hypointense ASC-derived signals in
animals representing the control group as well as the group treated with 5 × 104, 3 × 105, or 1 × 106 ASCs. b Differences in ΔCSI obtained 48 h
post MCAo are shown for all treatment groups. Groups are controls (n = 8 for MCAo = 45 min; n = 9 for MCAo = 90 min), and animals treated with
5 × 104 ASCs (n = 7; all MCAo = 45 min), 3 × 105 ASCs (both n = 6 for MCAo 45 min and 90 min), and 1 × 106 ASCs (n = 4 for MCAo = 45 min; n = 3
for MCAo = 90 min). The median of each treatment group is indicated as a red dotted line. Each column represents one animal with mean ΔCSI
obtained in seven brain slices per animal ± standard deviation. **p < 0.01 for control group vs. 1 × 106 and 5 × 104 ASC group, ***p < 0.001 for
control group vs. 3 × 105 ASC group. ASC adipose tissue derived stem cell, ΔCSI difference in cell signal intensity, MCAo middle cerebral
artery occlusion
Table 1 Group sizes, data range, median, and IQR for ΔCSI and infarct sizes obtained 48 h post MCAo
Variable ΔCSI Infarct size (%)
Treatment (number of ASCs) MCAo (min) Group size (n) Data range Median IQR Data range Median IQR
Control 45 8 −0.032 to 0.087 0.047 0.078 0.7 to 15.8 6.96 9.25
90 9 −0.143 to 0.156 0.055 0.066 1.1 to 17.2 3.23 6.76
5 × 104 45 7 0.054 to 0.179 0.089 0.088 0.5 to 9.3 4.63 5.94
3 × 105 45 6 0.079 to 0.136 0.099 0.034 1.7 to 10 5.86 3.83
90 6 0.079 to 0.143 0.093 0.046 1.1 to 13.1 6.82 6.43
1 × 106 45 4 0.014 to 0.2 0.157 0.12 3.8 to 26.1 13.37 16.93
90 3 0.083 to 0.379 0.12 – 4.2 to 20.6 19.64 –
ASC adipose tissue-derived stem cell, ΔCSI difference in cell signal intensity, IQR interquartile range, MCAo middle cerebral artery occlusion
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To evaluate the effect of ASC engraftment on infarct
size, the infarct volumes were determined as a percentage
of the individual total brain volume (data range, medians,
and IQRs for infarct size are shown in Table 1). The re-
sults revealed no influence of occlusion time on infarct
volume in the control group and the group receiving 3 ×
105 cells. For animals receiving 1 × 106 cells, the occlusion
times could not be compared due to restricted data for
the group undergoing MCAo for 90 min; however, due to
comparable infarct volumes in the first-mentioned groups,
a statistical comparison for every group was performed
independently of occlusion time. Infarct sizes were sig-
nificantly larger for animals receiving 1 × 106 cells
compared to the control group (p < 0.05) or animals
receiving 5 × 104 cells (p < 0.05). Infarct sizes in the
group receiving 3 × 105 ASCs lay between those of
control animals or animals injected with 5 × 104 cells
and the group receiving 1 × 106 cells (Fig. 2b).
T2* re-analysis and cell signal development
To investigate the time-course of ASC-derived signal in-
tensity, an additional MRI analysis was carried out 9
days post MCAo in the subacute to chronic stage of in-
farct development. The results revealed signal pattern
changes within the infarcted area (Fig. 3a; dotted line,
image 1) visible as hyperintense signals and most likely
deriving from development of vasogenic oedema, cell
lysis, and tissue cavitation, respectively, as shown by the
ADC map (Fig. 3a, image 2). This resulted in ambiguous
T2*-weighted hypointense signals indicating iron-
labelled ASCs or incipient tissue cavitation (Fig. 3a,
image 3) which required a re-analysis, leaving specific
ASC-derived hypointense voxels (Fig. 3a, image 4).
To evaluate possible changes in cell number between
both MRI examinations, an assessment of T2*-derived
voxel number was performed for both time points (data
range, medians, and IQRs for voxel numbers are shown
in Table 2). Due to the fact that not every animal under-
went both MRI examinations and voxel analysis data are
restricted to smaller populations compared to Fig. 1,
groups could not be compared for MCAo duration but
were distinguished in the figures. Animals receiving 3 ×
105 cells displayed significantly higher voxel numbers
than control animals as well as animals receiving 5 × 104
ASCs in both MRI examinations (p < 0.01). Voxel num-
bers did not change significantly between the two MRI
scans except for one animal in the 3 × 105 and one in
the 1 × 106 cell group. Because of insufficient data in the
1 × 106 cell group, animals injected with 1 × 106 cells
could not be analysed for statistics (Fig. 3b).
Fig. 2 MRI analysis of infarct size 48 h post-MCAo. a Representative T2-weighted images displaying infarction 48 h post MCAo are the
corresponding images to the T2*-weighted images shown in Fig. 1 and are derived from the same MRI slices and animals. b Differences
in infarct volumes obtained 48 h post MCAo are shown for all treatment groups. Groups are the same as in Fig. 1. The median for each
group is indicated as a red dotted line. Each column represents the infarct volume as a percentage of total individual brain volume for
one animal. *p < 0.05 for 1 × 106 ASC group vs. control group and 5 × 104 ASC group. ASC adipose tissue - derived stem cell, ΔCSI difference in cell
signal intensity, MCAo middle cerebral artery occlusion
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Fig. 3 T2* re-analysis and cell signal development. a Signal pattern changes within 9 days post MCAo in the infarct area (dotted line, image 1)
and consequential hyperintense signals displaying tissue changes as shown by the ADC map (image 2) are presented. Resulting ambiguous
T2*-weighted hypointense signals (image 3) were re-analysed, leaving specific ASC-derived hypointense voxels (image 4). b Differences in voxel
number obtained 48 h and 9 days post MCAo are shown for all treatment groups. Groups were controls (n = 5; n = 1 for MCAo = 45 min; n = 4 for
MCAo = 90 min), and animals treated with 5 × 104 ASCs (n = 7; all MCAo = 45 min), 3 × 105 ASCs (n = 7; n = 6 for MCAo = 45 min; n = 1 for MCAo
= 90 min), and 1 × 106 ASCs (n = 2; all MCAo = 90 min). The median for each group is indicated as a red dotted line for voxel numbers obtained 48
h post MCAo and as a green dotted line for voxel numbers obtained 9 days post MCAo. Each pair of columns represents values of one animal and
two MRI time points. **p < 0.01 for 3 × 105 ASC group vs. control group and 5 × 104 ASC group. ADC apparent diffusion coefficient, ASC adipose
tissue - derived stem cell, MCAo middle cerebral artery occlusion
Table 2 Group sizes, data range, median, and IQR for voxel numbers obtained 48 h and 9 days post-MCAo
Variable Voxel numbers
48 h post MCAo 9 days post MCAo
Treatment (number of ASCs) MCAo (min) Group size (n) Data range Median IQR Data range Median IQR
Control 45 1 1250 to 1686 1331 267 1361 to 1706 1490 230
90 4
5 × 104 45 7 931 to 2380 1106 875 793 to 1559 1369 433
3 × 105 45 6 1774 to 6611 2636 1132 1576 to 2943 2330 744
90 1
1 × 106 90 2 16795 and 3168 – – 7841 and 2162 – –
ASC adipose tissue-derived stem cell, IQR interquartile range, MCAo middle cerebral artery occlusion
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Residual infarct size 9 days post MCAo and cell migration
analysis
To investigate the long-term effect on infarct size,
residual infarct volumes 9 days post stroke were deter-
mined as an individual percentage of the infarct size ob-
tained 48 h post MCAo for each animal included in this
analysis (data range, medians, and IQRs for infarct size
are shown in Table 3). Due to the fact that not every ani-
mal underwent both MRI examinations the groups could
not be compared for MCAo duration but were distin-
guished in the figures. Infarct volumes of the control
group were comparable to those of the groups receiving
5 × 104 or 1 × 106 cells but differed significantly from the
group receiving 3 × 105 cells (p < 0.05), which showed
visibly reduced infarct sizes (Fig. 4a).
Due to improved stroke outcome in animals receiving
3 × 105 cells, the migration activity was assessed by com-
paring MRI signals visible in T2*-weighted images
between both MRI examinations. Differences in hypoin-
tense signals indicated cell movement towards the ischae-
mic border zone as shown in one animal from the group
receiving 3 × 105 ASCs. A strong T2*-weighted hypoin-
tense signal in the right ventricle of the ischaemic hemi-
sphere 48 h post MCAo (Fig. 4b, images 1 and 2), which
we also verified by voxel reanalysis, underwent signal loss
as shown by MRI analysis 9 days post stroke in the same
animal and MRI slide. At the same time, a hypointense
spot revealed as an ASC-derived signal appeared at the
ischaemic border zone in the striatum (Fig. 4b, image 3).
Under histology we identified the same location and ex-
amined it for possible stem cell signals using PB staining.
The staining revealed positive signals for VSOP-derived
iron oxide particles (Fig. 4b, image 4).
Discussion
In this study, we investigated the influence of three dif-
ferent IA injected doses of ASCs on stroke outcome and
stem cell homing. This was done via in vivo 9.4-T MRI
in a rat model of MCAo-induced stroke.
Over the last few years, many stem cell studies focus-
ing on stem cell administration, homing and tracking,
have mainly reported on the methological details, e.g.
the preparation of cell suspension of different stem cells,
injection parameters, stem-cell labelling, and tracking or
the time of stem-cell delivery [17, 28–33]. However, the
question of the right volume of stem cells being used for
transplantation was only addressed in one study inject-
ing different numbers of human neural progenitor cells
(NPCs) into the right striatum of male Wistar rats [34].
Darsalia and colleagues observed that transplantation of
greater numbers of grafted NSCs did not result in a
greater number of surviving cells or increased neuronal
differentiation. However, since a different type of stem
cell was used and the experimental settings differed, the
results are only partially comparable to ours. To our
knowledge, we are the first study raising the question of
whether, and to what extent, the number of IA engrafted
stem cells influences the parameters mentioned above
and if there is an optimal number recommended for this
administration.
Although the central nervous system (CNS) is an
immune-privileged region, a xenogenic transplantation
of human ASCs in a rat model may induce reactions of
the rodent immune system. This is a problem affecting
all studies testing human stem cells in rodent systems;
however, even allogeneic transplantation is being dis-
cussed as including the risk of immune rejection [35].
There are conflicting reports regarding the need for
immunosuppressive therapy after xenograft stem-cell
therapy for cell survival and differentiation, and it is still
unclear whether ASCs, despite their immunomodulatory
capacities, may elicit systemic immune reactions [36].
Similar to our previous work, where we were able to ob-
serve therapeutic efficacy and stimulation of endogenous
repair, we have stuck to this protocol and avoided
immunosuppressive therapy, and thus possible potential
effects on stroke progression and cell distribution [37].
Furthermore, our investigations where designed as a
proof-of-concept study with a survival time of only 14
Table 3 Group sizes, data range, median, and IQR for residual infarct sizes obtained 9 days post MCAo
Variable Residual infarct size (%)
Treatment (number of ASCs) MCAo (min) Animals (n) Data range Median IQR
Control 45 5 32.16 to 74.84 51.1 25.53
90 4
5 × 104 45 7 13.52 to 60.17 45.02 37.7
3 × 105 45 6 27.16 to 56.4 37.84 7.14
90 1
1 × 106 45 3 27.31 to 67.46 53.6 24.89
90 2
ASC adipose tissue-derived stem cell, IQR interquartile range, MCAo middle cerebral artery occlusion
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days, which is short compared to the 6 weeks used by,
for example, Hovakimyan et al. [36].
Studies show that the injured brain is more favourable
for stem cell migration than is the intact tissue. Evidence
from transplantation studies indicate that the intact
adult brain has a limited capacity to direct the differenti-
ation of transplanted stem cells, whereas the developing
brain and injured brain express morphogenic cues that
appear to foster donor plasticity [38]. Studies transplant-
ing NPCs either directly or IV have demonstrated that
cells need a triggering signal to undergo targeted migra-
tion in the rodent CNS and that neural NPCs trans-
planted into the un-injured adult rodent brain undergo
only limited and non-targeted migration [14, 39].
Another study using two sources of murine bone mar-
row stromal cells (BMSCs) demonstrated a seven-to
nine-fold increase in the number of adherent BMSCs
that accumulate in cerebral venules after focal transient
ischaemia compared to sham-operated mice [40]. How-
ever, the aim of the study was to investigate the effect of
different stem cell numbers on engraftment rate and
stroke outcome after transient brain ischaemia. There-
fore, we only included animals with MCAo-induced
stroke.
In the past few years the question of how the biodistri-
bution of systemically applied MSCs is regulated has also
included discussion about the advantages and disadvan-
tages of IV and IA administration. A very important
question in this therapeutic field is how to bring enough
stem cells to the targeted tissue. IV injection is a minim-
ally invasive, and therefore clinically highly relevant,
technique. On the other hand, it bears the disadvantage
of delayed and poor engraftment due to long-distance
migration and filtering organs; it was shown by several
studies that up to 80% of injected cells distribute to a
variety of non-targeted tissues, with most cells being
trapped in the lungs, followed by the liver and spleen
[41–44]. Consistently, studies comparing IV and IA ad-
ministration of NPCs and BMSCs observed no, or a
poor and late, engraftment in the ischaemic brain after
Fig. 4 Residual infarct size 9 days post MCAo and cell migration analysis. a Differences in residual infarct volumes obtained 9 days post MCAo are
shown for all treatment groups. Groups are controls (n = 9; n = 5 for MCAo = 45 min; n = 4 for MCAo = 90 min), and animals treated with 5 × 104
ASCs (n = 7; all MCAo = 45 min), 3 × 105 ASCs (n = 7; n = 6 for MCAo 45 min; n = 1 for MCAo = 90 min), and 1 × 106 ASCs (n = 5; n = 3 for MCAo =
45 min; n = 2 for MCAo = 90 min). The median for each group is indicated as a red dotted line. Each column represents residual infarct size for one
animal assessed as a percentage of the individual infarct size obtained 48 h post MCAo for each individual animal. *p < 0.05 for 3 × 105 ASC
group vs. control. b Migration activity in the ischaemic hemisphere (image 1, dotted line) of one animal treated with 3 × 105 ASCs is shown. A
strong hypointense signal in the right ventricle of the appending T2*-weighted image (image 2) obtained after 48 h decreases within 9 days post
MCAo with a new hypointense spot appearing in the striatum close to the infarct area (image 3). Signals are confirmed by voxel analysis.
Histological analysis of the same location reveals positive PB staining (blue signals, some supported by arrows in image 4, location # and §). ASC
adipose tissue - derived stem cell, MCAo middle cerebral artery occlusion, PB Prussian blue
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IV injection [14, 16]. A second factor to bear in mind is
the formation of emboli in lung vessels [42]. Cell
culture-expanded MSCs are relatively large cells with an
average size of 30 μm. Therefore, obstructive events dur-
ing lung passage are expected after MSC administration
which is supported by their relatively high adhesion cap-
acity and their tendency to aggregate, leading to clogging
of capillaries [42, 45, 46]. Contrary to the observation of
MSC retention in the lungs, one study analysing the bio-
distribution of BMSCs after IA injection found a de-
creased deposition in the lungs and increased uptake in
other organs, especially in the liver [47]. With regard to
engraftment time and rates, studies comparing both ap-
plication routes have demonstrated a major association
between IA application and the early and increased
accumulation in therapeutic target tissues [14, 16]. How-
ever, this was associated with an impeded cerebral blood
flow and higher mortality rates. In conclusion, the IA
route of administration seems to be effective in avoiding
pulmonary entrapment and may thus improve the bio-
distribution and bioavailability of transplanted MSCs in
clinically relevant issues, e.g. for tissue repair.
As mentioned, IA delivery was reported to result in
higher mortality rates compared to the IV application
[14, 16–18]. Since 1 × 106 stem cells are the standard
amount for transplantation in rodents, we also included
this number in our study, but we had tremendous diffi-
culties obtaining enough data due to mortality rates be-
ing twice as high as for the other groups. Since mortality
rates were only 0–33% in the other groups we cannot
confirm the idea of IA delivery increasing the mortality
rate per se. We hypothesize the outcome may depend
on the cell amount because, in the case of IA injection, a
larger cell number could be brought to the brain more
quickly, bypassing systemic organs. As a consequence
this may lead to increased mortality due to impeded
CBF [16]. But since we have not examined other organs
where cells are typically found after systemic application
(e.g. lungs) we cannot exclude the possibility of pulmon-
ary embolism resulting from cells bypassing the brain.
The comparison of infarct volumes reflected the re-
sults we obtained from mortality rates since application
of 1 × 106 ASCs led to an increase in infarct size. This
corresponds to Lu et al. who obtained similar results in
two dogs after injection of 3 × 106 cells [15]. In addition
to the impeded blood flow observed by Walczak et al.
[16], cell injection could lead to occlusion of cerebral
microvessels and thus to comprised microvascular circu-
lation and increased infarct size. Another possibility
leading to disturbed blood flow is the fact that MSCs
have been shown to possess blood clotting properties by
triggering the pro-coagulatory cascade via surface
expression of tissue factors. This in turn may cause thrombo-
embolism promoting mechanical vascular obstruction [48–
51]. This closes the loop to immunological complications of
intravascular stem-cell applications derived by strong im-
munosuppressive properties that may amplify the post-
stroke immune deficiency syndrome and hence the risk for
infections [52–55]. However, the majority of pre- and clinical
data support the notion that embolic events are very rare
and in the majority of cases are a mild side effect of intraven-
ous infusion, which can be easily circumvented by adding
anticoagulants such as heparin during cell infusion [56].
In our study, an occlusion time-dependent effect could
not be observed possibly due to the model-adherent vari-
ability in infarct sizes we obtained. At 9 days post MCAo,
the mean infarct size in the 3 × 105 ASC group decreased
about 30% whereas infarct sizes in the other groups were
comparable to the infarct size in the control group. Where
animals received 1 × 106 ASCs this is consequential due to
higher initial infarct sizes, but for the group receiving 5 ×
104 ASCs one could speculate that this cell amount is not
high enough to affect stroke recovery positively. A positive
reduction of infarct size up to 54% could also be observed
in previous studies after IA injection in Wistar and
Sprague-Dawley rats, but since 1 × 106 cells or more were
used this is contrary to what we found [18, 57]. However,
mortality rates were not discussed and experimental
settings were slightly different which, in general, makes it
difficult to compare results.
As described previously and confirmed in vivo, T2*-
weighted images revealed engrafted cells scattering dis-
cretely throughout the entire lesion area [14–16]. This
agrees with the theory that transplanted cells are
attracted by, and interact with, tissue regions undergoing
degeneration and reorganization [58]. In the acute stage,
48 h post stroke differences in CSI depended on the
injected cell number which we could also sensitively
observe by 9.4-T MRI. However, cell signal analysis in
the subacute to chronic stage 9 days post MCAo was
difficult due to tissue changes initiated by stroke and
followed by vasogenic oedema, cell lysis, and the begin-
ning of tissue cavitation, as indicated by the ADC maps
[59–61]. Therefore, T2*-weighted signals had to be re-
analysed and ASC-derived signals be identified. We
could solve this problem by performing a re-analysis of
T2*-weighted images for reliable identification of voxels
deriving from ASC signals. After successful voxel ana-
lysis we observed no difference in voxel numbers
between both MRI examinations in most of the animals
that we analysed. Contrary to our findings, Lu et al. ob-
served a clear signal attenuation 14 days post MCAo
using 3-T MRI after transplantation of VSOP-labelled
MSCs [15]. Since the MRI detection threshold of
labelled cells depends on particle concentration per cell,
cell density after integration, and MRI parameters such
as field strength, 3-T MRI analysis might involve
detection limits due to lower contrast-to-noise ratio
Grudzenski et al. Stem Cell Research & Therapy  (2017) 8:96 Page 10 of 14
compared to 9.4-T imaging [62, 63]. As Lu et al. men-
tioned, this may lead to the assumption of signal loss.
Since we could not observe a signal loss 9 days post
MCAo that would have implied cell degradation, we
assumed that this result may indicate predominantly vital
ASCs, with them being potentially able to proliferate and
migrate actively within the brain parenchyma. Subsequent
histological analysis using PB staining as a reliable tool for
VSOP-labelled cell visualization revealed PB-positive loca-
tions being also positive for VSOP fluorescence and hu-
man markers. The fact that almost all the cell cytoplasm
of VSOP-labelled ASCs were distinctively blue showed
that neither excessive cell degradation nor excessive prolif-
eration activity had taken place because this would have
led to weakened staining results in daughter cells as
shown in our obtained growth curves. We further tested
proliferation activity using Ki67. Positive signals indicated
that at least some ASCs had started proliferation. How-
ever, our findings do not exclude the possibility of cell
degradation taking place or the presence of resting cells at
other locations. Despite some challenges due to tissue
changes, we consider T2*-imaging as a very promising
tool that might also offer further valuable information
about tissue oxygenation in animal and human studies for
future applications [64, 65].
Because of the observed reduction in infarct size in
the group receiving 3 × 105 ASCs, we were interested in
migration activity within the brain parenchyma leading
to promotion of brain remodelling and neurological re-
covery [12]. From early observations in the literature we
know that stem cells are able to migrate to an ischaemic
area very soon after transplantation [66–68]. After ana-
lysis of the MRI data of all our groups we found a strong
hypointense signal in the right ventricle and striatum of
one animal treated with 3 × 105 cells. This signal was
confirmed by voxel analysis and was attenuated between
48 h and 9 days, while a new signal appeared right at the
ischaemic border. Histological analysis of this animal re-
vealed residual ASCs in the ventricle and “new” ASCs at
the ischaemic border at this location. Although this
observation looks very promising, especially due to a
decline in infarct volume in the 3 × 105 cell group, the
limitation must be noted that this observation could
only be made in one animal. The reason for this can
probably be found in the fact that locally and temporar-
ily highly limited processes such as cell migration are
difficult to capture and that more consecutive MRI
examinations and more animals per group may be
necessary to solidify our observation.
We are aware of limitations in our study; this applies
in particular to the group sizes. As we have already men-
tioned, the 1 × 106 cell group showed mortality rates
twice as high as the other groups. Since mortality rates
are rarely discussed in comparable settings, this was
surprising for us. The only indications in the literature
can be found in a study of Li et al. who observed a mor-
tality rate of 41% in Wistar rats being injected IA with
1 × 106 NPCs 24 h after transient 2 h ischaemia, as well
as by Walczak et al. who observed a mortality rate of
67% in Wistar rats being injected IA with 1 × 106 BMSCs
30 min after transient 2 h ischaemia [14, 16]. Further-
more, we had limited numbers of animals being exam-
ined for voxel analysis and residual infarct size post
stroke since not every animal underwent both MRI ex-
aminations. Nevertheless, the essential statements con-
cerning the effect of different stem cell numbers on
engraftment rate and stroke outcome after transient
brain ischaemia could be validated with the numbers we
had. For upcoming studies we will have to take the limi-
tations, e.g. mortality rate, of this study into account.
Future histological analysis of the animals will pursue
interesting issues involving the question of cell location
and distribution within the brain after cell delivery and
how the initially injected cell number affects the amount
and percentage of cells migrating into the brain.
Conclusions
In conclusion, although IA delivery of SCs is a more inva-
sive method compared to IV injection, it offers the advan-
tage of direct targeting of the damaged tissue. Since cells
are solid, they likely have the big disadvantage of provoking
impeded CBF and vessel occlusion after injection of high
cell numbers. In therapeutic doses, however, systemically
delivered SCs may promote brain remodelling and induce
functional neurological recovery. Therefore, the future diffi-
culty will be to achieve high cellular engraftment in patients
receiving stem cell treatment without the side effects men-
tioned above. The correct amount of stem cells could be a
first step towards the use of an efficient chemoattractive
gradient released at the site of the brain lesion.
Additional files
Additional file 1: Supplemental material. (DOCX 18 kb)
Additional file 2: Figure S1. Influence of VSOP labelling on cell vitality
and growth behaviour. LDH release did not differ for unlabelled (negative
control) and VSOP-labelled ASCs. Both differed significantly from positive
control. *p < 0.05 for negative control and VSOP-labelled cells vs. positive
control (A). Growth curves and fraction of dead cells did not differ between
labelled and unlabelled cells at any time (diagram). Growth curves of vital
cells increased significantly during the observation period. VSOP density in
cytoplasm decreased within 9 days (images). *p < 0.05 for increased cell
growth up to 14 days for VSOP-labelled and unlabelled ASCs (B). ASC
adipose tissue-derived stem cell, LDH lactate dehydrogenase, VSOP very
small superparamagnetic iron oxide particles. (TIF 6166 kb)
Additional file 3: Figure S2. Identification and localisation of
VSOP-labelled ASCs via PB staining and VSOP fluorescence.
Representative images of a PB-stained brain section 14 days post-MCAo
of an animal treated with ASCs and enlarged locations within the brain
slice. A single ASC is visualized (image 3) and distinguished from the
unlabelled rat brain cell. ASCs correlate with locations of VSOP fluorescence
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obtained in a neighbour slice (image 8a, blue = DAPI stained cell nuclei,
green = VSOPs). ASC adipose tissue-derived stem cell, DAPI 4',6-diamidino-2-
phenylindole, MCAo middle cerebral artery occlusion, PB Prussian blue, VSOP
very small paramagnetic iron oxide particles. (TIF 7415 kb)
Additional file 4: Figure S3. Identification and viability testing of ASCs
via staining of human mitochondria and Ki67. Representative images of
PB-positive areas (left images) co-localized with locations positive for human
mitochondria (B) and Ki67 (C) (DAB-positive signal, middle images) in
neighbour slices whereas negative controls showed no DAB signal (right
images). ASC adipose tissue-derived stem cell, DAB 3,3'-diaminobenzidine,
PB Prussian blue. (TIF 7971 kb)
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